Fortune

A Biotech Boom in China? Not Just Yet

Chinese biopharma stocks have lucrative potential, but realizing gains will involve some growing pains.
BeiGene’s share price has fallen 11.3% since its IPO.

RECENT REGULATORY changes in China have led to an outpouring of enthusiasm from investors and biopharmaceutical companies looking to gain a foothold in one of the world’s major markets—a

You're reading a preview, sign up to read more.

More from Fortune

Fortune2 min read
Apparel And Home Goods: The So-so Side Of Sears
SEARS’ HUGE appliance and tools businesses distinguished it from rivals like J.C. Penney and Macy’s, which were best known for apparel. The problem: People buy a fridge or power drill only once every few years, while they stock up on clothing three o
Fortune2 min read
Census Security
EVERY 10 YEARS, the U.S. Census Bureau conducts a nationwide survey that sets the terms for the country’s democracy. The questionnaire yields rich data, including names, street addresses, ages, races, ethnicities, and other details. That creates a tr
Fortune2 min read
Tech’s Unicorns Feast At The IPO Trough
All signs point to a record-breaking year for U.S. tech IPOs, as hot companies like Uber, Lyft, and Pinterest cash in.